Appendix

Table of Contents

The Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma 2013 Edition Preface .......................................................................................................................... 8
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations ................................................................. 11
Explanation of surveillance algorithms/diagnostic algorithms for hepatocellular carcinoma .... 18
Explanation of treatment algorithms for hepatocellular carcinoma ............................................. 20

Chapter 1 ■ Prevention .................................................................................................................. 24
Introduction ................................................................................................................................. 24
Section 1 Interferon Therapy ........................................................................................................ 25
CQ1 Does interferon therapy chronic hepatitis C infection effectively prevent HCC? ..................... 25
Section 2 Liver Support Therapy .................................................................................................. 30
CQ2 Does liver support therapy effectively prevent HCC? ............................................................ 30
CQ3 Does antiviral therapy against chronic hepatitis B infection effectively prevent HCC? .......... 32

Chapter 2 ■ Diagnosis and Surveillance ....................................................................................... 38
Section 1 Surveillance ................................................................................................................ 38
Introduction ................................................................................................................................. 38
CQ4 Who are eligible candidates for surveillance? ................................................................. 39
CQ5 Does surveillance improve prognosis? ............................................................................. 46
CQ6 What methods are used in surveillance? ............................................................................. 49
CQ7 What size (cm) of atypical liver nodules using dynamic CT or dynamic MRI should be further examined? .......................................................... 54
Section 2 Tumor Markers ........................................................................................................ 56
Introduction ................................................................................................................................. 57
CQ8 Is it useful to measure two or more tumor markers for diagnosing HCC? ......................... 59
CQ9 Is tumor marker measurement an effective post-treatment indicator for HCC? ............... 61
Section 3 Diagnostic Imaging ..................................................................................................... 61
Introduction ................................................................................................................................. 61
CQ10 What are the best tests for diagnosing early-stage HCC in patients with cirrhosis? .......... 62
CQ11 What are the best tests for diagnosing typical HCC in high-risk patients? ................. 69
CQ12 Is angiography necessary before HCC treatment? .................................................. 75
CQ13 Is CTAP/CTHA necessary before HCC treatment? ............................................. 79
CQ14 What test methods are useful for diagnosing liver tumors in patients
with decreased kidney and liver function? ................................................................. 80
CQ15 How should contrast media be used for diagnostic imaging of HCC? ................. 84
CQ16 Are brain MRI, chest CT, bone scintigraphy, and FDG-PET necessary
for determining the stage of HCC? ........................................................................... 91
CQ17 Does contrast-enhanced ultrasound improve the ability to diagnose HCC? ........ 94
CQ18 Is contrast-enhanced ultrasound useful for determining
the treatment outcomes of percutaneous ablation therapy and TACE? ................ 99

Chapter 3 ■ Surgery .................................................................................................. 104
Introduction .............................................................................................................. 104
Section 1  Indications for Surgery/Surgical Procedures ............................................. 107
  CQ19 What assessment modalities are appropriate for evaluating liver function
  prior to liver resection?
    What are the indications for surgery from the perspective of liver function? .......... 107
  CQ20 What is the standard surgical procedure for liver resection? ......................... 113
  CQ21 What are the indications for liver resection in terms of tumor condition? ........ 118
Section 2  Prognostic Factors .................................................................................... 122
  CQ22 What are the prognostic factors after liver resection? .................................... 122
  CQ23 Does the size of the resection margin affect prognosis? ................................. 125
  CQ24 Does anatomical liver resection affect prognosis? .......................................... 128
Section 3  Perioperative Management ........................................................................ 130
  CQ25 Is proactive, perioperative administration of blood products recommended? ... 130
  CQ26 Does hepatic pedicle clamping and decreased central venous pressure
decrease bleeding during liver resection? .............................................................. 133
  CQ27 Is abdominal drain placement necessary for liver resection? ......................... 136
Section 4  Adjuvant Therapy ...................................................................................... 137
  CQ28 Does neoadjuvant chemotherapy improve prognosis after liver resection? .... 137
  CQ29 Does adjuvant chemotherapy improve prognosis after liver resection? ........ 140
Section 5 Liver Transplantation .................................................................................. 143
Introduction .............................................................................................................. 143
  CQ30 Does pretransplantation tumor downstaging improve
  the prognosis of liver transplantation? ................................................................. 145
  CQ31 What are the indications of liver transplantation for HCC? ......................... 148

Chapter 4 ■ Percutaneous Ablation Therapy .............................................................. 156
Introduction .............................................................................................................. 156
  CQ32 Who are eligible candidates for percutaneous ablation therapy? .................. 157
CQ33 How should a type of percutaneous ablation therapy be selected? .......................... 162
CQ34 Does a combination of TACE and percutaneous ablation therapy improve prognosis? .......................... 166
CQ35 Are contrast-enhanced ultrasound and fusion imaging useful guides for percutaneous ablation therapy? .......................... 169
CQ36 What type of diagnostic imaging is useful for assessing treatment response of percutaneous ablation therapy? .......................... 172

Chapter 5 ■ Transcatheter Arterial Chemoembolization (TACE) .......................... 175
Introduction ............................................................................................................. 175
CQ37 Who are eligible in TACE/TAE? ................................................................. 176
CQ38 What type of embolic material or anticancer agent should be used for TACE/TAE? ................................................................. 184
CQ39 How should repeat TACE/TAE be scheduled? ............................................. 193
CQ40 What types of diagnostic imaging techniques are useful for evaluation of the treatment effect of TACE? ................................................................. 196

Chapter 6 ■ Chemotherapy ..................................................................................... 201
Introduction ............................................................................................................. 201
CQ41 Who are eligible candidates for systemic chemotherapy? .............................. 202
CQ42 Does hepatic arterial infusion chemotherapy improve prognosis? ...................... 205
CQ43 Which chemotherapy regimens (drug regimens) are effective? .......................... 206
CQ44 Is hormone therapy effective? ........................................................................ 210
CQ45 What are the predictive and prognostic factors for the treatment outcomes of chemotherapy? ................................................................. 212
CQ46 How should the treatment outcome of chemotherapy be determined? ................ 213
CQ47 What are the adverse effects of chemotherapy, and how should they be treated? ............................................................................................................. 215
Appendix table ......................................................................................................... 219

Chapter 7 ■ Radiation Therapy ................................................................................ 222
Introduction ............................................................................................................. 222
CQ48 Is three-dimentional (3D) conformal radiation therapy useful for HCC? .............. 223
CQ49 Is stereotactic body radiation therapy useful for HCC? ....................................... 228
CQ50 Is particle radiation therapy [proton therapy, heavy particle (carbon ion) radiation therapy] useful for HCC? ................................................................. 232
CQ51 Is radiation therapy indicated for distant metastases from HCC? ......................... 235
Chapter 8 ■ Post-Treatment Surveillance, Prevention and Treatment of Recurrence

Introduction

CQ52 How should patients be followed up after liver resection and percutaneous ablation therapy?

CQ53 What methods are effective for preventing recurrence after liver resection and percutaneous ablation therapy?

CQ54 What methods are effective for preventing recurrence after liver transplantation?

CQ55 What treatments are effective against recurrence after liver transplantation?

CQ56 What treatments are effective against recurrence after percutaneous ablation therapy?

CQ57 What treatments are effective against recurrence after liver transplantation?

Comments from the Health Economics Committee

■ Health Economics Perspective on Clinical Practice Guidelines for Hepatocellular Carcinoma, 2013 Edition

- Regarding CQ43 in Particular -

Literature Search Queries